These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27718183)

  • 1. Development of the CpG Adjuvant 1018: A Case Study.
    Campbell JD
    Methods Mol Biol; 2017; 1494():15-27. PubMed ID: 27718183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years.
    Hyer RN; Janssen RS
    Vaccine; 2019 Sep; 37(39):5854-5861. PubMed ID: 31431412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
    Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
    Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
    Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L
    Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
    Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
    Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine.
    Zhang X; He P; Hu Z; Wang X; Liang Z
    Virol J; 2011 Feb; 8():78. PubMed ID: 21342531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.
    Cooper CL; Davis HL; Morris ML; Efler SM; Adhami MA; Krieg AM; Cameron DW; Heathcote J
    J Clin Immunol; 2004 Nov; 24(6):693-701. PubMed ID: 15622454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmids enriched with CpG motifs activate human peripheral blood mononuclear cells in vitro and enhance th-1 immune responses to hepatitis B surface antigen in mice.
    Chen Z; Cao J; Liao X; Ke J; Zhu S; Zhao P; Qi Z
    Viral Immunol; 2011 Jun; 24(3):199-209. PubMed ID: 21668361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice.
    Qin W; Jiang J; Chen Q; Yang N; Wang Y; Wei X; Ou R
    Cell Mol Immunol; 2004 Apr; 1(2):148-52. PubMed ID: 16212903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
    Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
    J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin vaccination via fractional infrared laser ablation - Optimization of laser-parameters and adjuvantation.
    Scheiblhofer S; Strobl A; Hoepflinger V; Thalhamer T; Steiner M; Thalhamer J; Weiss R
    Vaccine; 2017 Mar; 35(14):1802-1809. PubMed ID: 28117172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
    Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
    Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
    Heyward WL; Kyle M; Blumenau J; Davis M; Reisinger K; Kabongo ML; Bennett S; Janssen RS; Namini H; Martin JT
    Vaccine; 2013 Nov; 31(46):5300-5. PubMed ID: 23727002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults.
    Hyer R; McGuire DK; Xing B; Jackson S; Janssen R
    Vaccine; 2018 May; 36(19):2604-2611. PubMed ID: 29628151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.
    Malanchère-Brès E; Payette PJ; Mancini M; Tiollais P; Davis HL; Michel ML
    J Virol; 2001 Jul; 75(14):6482-91. PubMed ID: 11413315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.
    Sablan BP; Kim DJ; Barzaga NG; Chow WC; Cho M; Ahn SH; Hwang SG; Lee JH; Namini H; Heyward WL
    Vaccine; 2012 Mar; 30(16):2689-96. PubMed ID: 22342916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust Immune Responses Elicited by a Hybrid Adjuvant Based on β-Glucan Particles from Yeast for the Hepatitis B Vaccine.
    Liu H; Meng Z; Wang H; Zhang S; Huang Z; Geng X; Guo R; Wu Z; Hong Z
    ACS Appl Bio Mater; 2021 Apr; 4(4):3614-3622. PubMed ID: 35014447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice.
    Li Y; Kandimalla ER; Yu D; Agrawal S
    Int Immunopharmacol; 2005 Jun; 5(6):981-91. PubMed ID: 15829414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.